Status:
COMPLETED
Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine
Lead Sponsor:
Janssen-Ortho LLC
Collaborating Sponsors:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Conditions:
Migraine
Classic Migraine
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the impact of topiramate (migraine prevention medicine) on the effectiveness of almotriptan malate (acute migraine medicine) when treating acute migraine heada...
Detailed Description
Migraine afflicts greater than 28 million adults in the United States. Acute treatments, such as almotriptan malate, target the symptoms of a migraine attack. Preventive treatments, such as topiramate...
Eligibility Criteria
Inclusion
- Have a history of migraine headaches for at least 6 months
- Experience 3-12 migraines per month
- Able to take oral medication
- Able to complete the electronic diary (Personal Digital Assistant-PDA).
Exclusion
- You will not be able to participate in the study if you previously discontinued Topiramate or Almotriptan because it did not make you feel better or it made you feel different
- Have 15 or more headache days a month
- Experience migraine aura without a headache
- Already on a migraine preventative medicine.
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
406 Patients enrolled
Trial Details
Trial ID
NCT00210496
Start Date
June 1 2005
End Date
June 1 2007
Last Update
May 17 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.